Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia

• Дата: 2023
• Автори: Langabeer, S.E., Haslam, K., Crampe, M., MacDonagh, B., McHugh, J.
• Формат: Стаття
• Мова: Англійська
• Опубліковано: PH Akademperiodyka 2023
• Теми: T240A ABL1
• Онлайн доступ: https://exp-oncology.com.ua/index.php/Exp/article/view/2019-1-1
• Назва журналу: Experimental Oncology

Over the last twenty years, chronic myeloid leukemia (CML) has come to be considered a paradigm for rationally selected, targeted inhibition of the disease-specific, BCR-ABL1 tyrosine kinase activity. However, a minor but significant numbers of patients either fail, or have suboptimal respo...